ADMA Biologics ADMA Additional Paid-In Capital
Additional Paid-In Capital at other companies
Other financials
Where this comes from
Reported directly by ADMA Biologics in its filing.
Tagged under the XBRL concept us-gaap:AdditionalPaidInCapital.
The official record: ADMA Biologics’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about ADMA Biologics's additional paid-in capital.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is ADMA Biologics's additional paid-in capital?
- ADMA Biologics (ADMA) reported additional paid-in capital of $649.8M in Q1 2026.
- How has ADMA Biologics's additional paid-in capital changed year-over-year?
- ADMA Biologics's additional paid-in capital decreased by 0.8% year-over-year, from $655.07M to $649.8M.
- What is the long-term trend for ADMA Biologics's additional paid-in capital?
- Over 5 years (2020 to 2025), ADMA Biologics's additional paid-in capital has grown at a 9.4% compound annual growth rate (CAGR), from $428.7M to $671.04M.
- What does additional paid-in capital mean?
- Capital received from shareholders in excess of par value — the premium investors paid over the nominal value of shares at issuance, plus stock-based compensation effects.